Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 15 points (-0.1%) at 17,673 as of Wednesday, Nov. 19, 2014, 12:10 PM ET. The NYSE advances/declines ratio sits at 967 issues advancing vs. 1,986 declining with 177 unchanged. The Drugs industry currently sits down 0.5% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include Gilead ( GILD), down 1.6%, Pfizer ( PFE), down 0.8% and Actavis ( ACT), down 0.6%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Eli Lilly and ( LLY) is one of the companies pushing the Drugs industry lower today. As of noon trading, Eli Lilly and is down $0.58 (-0.9%) to $67.20 on light volume. Thus far, 1.1 million shares of Eli Lilly and exchanged hands as compared to its average daily volume of 4.1 million shares. The stock has ranged in price between $67.08-$67.66 after having opened the day at $67.66 as compared to the previous trading day's close of $67.78. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. Eli Lilly and has a market cap of $74.9 billion and is part of the health care sector. Shares are up 32.9% year-to-date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Eli Lilly and a buy, 1 analyst rates it a sell, and 8 rate it a hold. TheStreet Ratings rates Eli Lilly and as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.